Article
Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non-Small-Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Dec 2022
Yue Dongsheng, Xu Shidong, Wang Qun, Li Xiaofei, Shen Yi, Zhao Heng, Chen Chun, Mao Weimin, Liu Wei, Liu Junfeng, Zhang Lanjun, Ma Haitao, Li Qiang, Yang Yue, Liu Yongyu, Chen Haiquan, Zhang Zhenfa, Zhang Bin, Wang Changli
Abstract excerpt
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.